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Abstract 
Treatment of patients with chronic obstructive pulmonary disease (COPD) in stable phase of the 
pathological process involves continuous inhalation therapy. However, according to the studies, 
adherence to regular use of inhalers varies from 30 to 50 %. 
The aim: determine the adherence to continuous inhalation therapy in patients with COPD, living in the 
Dnieper region. 
Materials and Methods: we have examined 60 COPD patients. Examination of patients included 
general clinical methods, assessment of the regularity of visits to «Spiro» office, spirometry. Adherence 
to the drug therapy was determined by 8-item Morisky Medication Adherence Scale (MMAS-8). 
Results: the level of adherence of COPD patients depends on the regularity of contact with the doctor 
and does not depend on gender. The main cause of non-adherence of COPD patients is the fact that 
sometimes patients forget to take medication, among other reasons there are major financial difficulties. 
The risk group as to the reduced adherence to inhalation therapy includes patients with vague bronchial 
obstruction. Given the difficulty of obtaining adequate responses to some questions of MMAS-8, one 
should consider the necessity of developing a new questionnaire for these patients. 
 
Keywords: Chronic obstructive pulmonary disease, adherence to inhaled therapy, 8-item Morisky 
Medication Adherence Scale. 
 
1. Introduction 
Currently, one of the most urgent problems of medicine, according to the World Health 
Organization, is the lack of patients’ adherence to drug therapy [1]. 
The low level of adherence in patients with chronic diseases is the main cause of reduced 
expression of therapeutic effect; it significantly increases the probability of complications, 
leading to the decrease in quality of life and increased healthcare costs [2]. Experts estimate, 
that the long-term adherence of patients to any treatment regardless of disease does not exceed 
50 % [1]; among patients with chronic diseases, this figure ranges from 43 to 78 % [3, 4]. Patients 
with chronic obstructive pulmonary disease (COPD) are no exception, and they are included 
into the group with the lowest level of adherence [5]. 
COPD refers to the disease with vague clinical symptoms in the stable phase of the 
pathological process, especially in early stages. Most studies have shown that chronic diseases 
without manifested symptoms are predictors of poor adherence to drug therapy. The absence 
of acute symptoms reduces the motivation of patients to long-term use of medications [6]. 
Treatment of patients with COPD in stable phase of the pathological process involves 
continuous medication intake [7]. Preference is given to inhalation administration, as it provides 
the direct penetration of the drug in the airways, and thus facilitates more effective medication 
exposure and reduces the potential risk of adverse systemic effects. However, according to the 
studies, adherence to regular use of inhalers varies from 30 to 50 % [8]. The low adherence to 
inhalation therapy in patients with COPD was identified as the main factor that leads to 
emergency hospital admission to in-patient department [9, 10]. 
Of particular importance is the problem of non-adherence to medical advice under the 
conditions of economic crisis, when there is the deterioration in adherence and increased 
morbidity because of declining real incomes and increased cost of drugs [11]. Insufficient 
adherence to treatment is also caused by the reduction of tax benefits for drugs, and this in turn 
affects the efficiency of therapy [12]. According to the research, the lowest adherence was 
observed in patients who live alone, the highest – in patients whose relatives were able to pay 
for expensive drugs [13].
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The aim of our research was to determine the adherence to 
continuous inhalation therapy in patients with COPD, living 
in the Dnieper region. 
 
2. Materials and Methods 
We have examined 60 COPD patients in stable phase of the 
pathological process during at least two months. The patients 
were observed for a long time in the regional consultative-
diagnostic office «Spiro» of Municipal institution 
«Dnipropetrovsk City Clinical Hospital No. 6» of 
Dnipropetrovsk regional council. 
Since in all examined patients the diagnosis of COPD was 
already verified (according to the Order of Ministry of Public 
Health of Ukraine as of 27.06.2013 No. 555) [14], the 
consultant doctor at «Spiro» office scheduled the regular 
visits (once every 2-3 months, and if necessary) in order to 
control the ventilation function of the lungs, accuracy of 
inhalation technique of drugs and, if necessary, to correct the 
treatment regimen. 
Patients were aged from 47 to 84 years (average age – 65.4 ± 
1.0 years), disease duration ranged from 1 to 36 years 
(average duration – 7.3 ± 0.8 years); there were 50 (83.3 %) 
men and 10 (16.7 %) women.  
Examination of patients included general clinical methods 
(collection of complaints, anamnesis, physical examination), 
assessment of the regularity of visits to «Spiro» office, 
spirometry with definition of forced expiratory volume in the 
first second (FEV1) before and after tests with bronchodilators 
(salbutamol – 400 mcg), forced vital lung capacity (FVC) 
using the unit «Master Screen Body / Diff» («Jaeger», 
Germany). 
In all patients with COPD, FEV1 / FVC level was less than 
0.7. Three (5.0 %) patients had bronchial obstruction of I 
degree (FEV1 – (91.3 ± 2.9) % pred.), 20 (33.3 %) – bronchial 
obstruction of II degree (FEV1 – (60.2 ± 2.2) % pred.), 34 
(56.7 %) – bronchial obstruction of III degree (FEV1 – (40.2 ± 
1.7) % pred.) and 3 (5.0 %) – bronchial obstruction of IV 
degree (FEV1 – (25.0 ± 1.7) % pred.). 
Adherence to the drug therapy was determined by Morisky-
Green questionnaire (8-item Morisky Medication Adherence 
Scale (MMAS-8)), which includes eight questions (questions 
are listed in Table 1) [15]. Upon scoring 0 – 5 points, the low 
level of adherence was established; 6 - 7 points – the medium 
adherence; 8 points – the high level of adherence to inhalation 
therapy [15]. 
All patients received medical treatment according to clinical 
group of COPD in concordance with the Order of Ministry of 
Public Health of Ukraine No. 555 as of 27.06.2013 [14]. 
The obtained results were processed with standard methods of 
assessment of variational series. The difference between the 
comparative values was considered reliable at p < 0.05. 
Calculations were performed using the software «Statistica 
6.1» («Stat Soft», USA). 
 
3. Results and Discussion 
The obtained results showed that 24 (40.0 %) out of 60 
patients had the high level of adherence to inhalation therapy, 
15 (25.0 %) patients – medium adherence, i.e., were in the 
risk group of non-adherence, and 21 (35.0 %) – the low level 
of adherence. The level of adherence was significantly 
dependent on the regularity of patient’s contact with the 
physician (r = 0.489, p < 0.001). Relationship between the 
patient’s gender and adherence to drug therapy was not found 
(r = - 0.115, p > 0.05). 
When analyzing the answers to the first and eighth questions 
of MMAS-8, the attention was attracted by the fact that 
almost 50 % of patients at least sometimes forgot to take 
medications, missed the intake, and at the same time one can 
assume that more than half of patients never forgot to take 
them (Table 1). Most likely, they either did not understand the 
question, or tried to look better in the eyes of the doctor. 
Correlation analysis showed no relationship between age and 
the fact that patients forgot to take medications (r = 0.129, p > 
0.05). The latter is most likely due to the fact that the vast 
majority of patients with COPD were of quite venerable age 
(50 and older). 
 
Table 1: Answers of COPD patients (n = 60) to MMAS-8 questionnaire 
 
No. Questions 
Number of patients with 
scored points (abs. / %) 
0 points 1 point 
1. Do you sometimes forget to take your pills? (Yes - 0 point, No – 1 point) 27 (45,0 %) 33 (55,0 %) 
2. 
People sometimes miss taking their medications for reasons other than forgetting. Thinking over 
the past two weeks, were there any days when you did not take your medicine? (Yes - 0 point, 
No – 1 point) 
19 (31,7 %) 41 (68,3 %) 
3. Have you ever cut back or stopped taking your medicine without telling your doctor because you felt worse when you took it? (Yes - 0 point, No – 1 point) 7 (11,7 %) 53 (88,3 %) 
4. When you travel or leave home, do you sometimes forget to bring along your medicine? (Yes - 0 point, No – 1 point) 9 (15,0 %) 51 (85,0 %) 
5. Did you take all your medicine yesterday? (Yes - 1 point, No – 0 point) 9 (15,0 %) 51 (85,0 %)
6. When you feel like your symptoms are under control, do you sometimes stop taking your medicine? (Yes - 0 point, No – 1 point) 15 (25,0 %) 45 (75,0 %) 
7. Taking medicine every day is a real inconvenience for some people. Do you ever feel hassled about sticking to your treatment plan? (Yes - 0 point, No – 1 point) 10 (16,7 %) 50 (83,3 %) 
8. How often do you have difficulty remembering to take all your medicine? (Never/rarely – 1 point; Once in a while – 0 point; Sometimes – 0 poin; Usually – 0 point; All the time – 0 point) 29 (48,3 %) 31 (51,7 %) 
 
Analysis of patients’ responses to the second question showed 
that every third person missed taking medication for other 
reasons besides forgetfulness (Table 1). Clarification during 
the individual interview indicated that 13 (68.4 %) of 
respondents had some financial difficulties, 4 (21.1 %) 
patients – doubts about the correctness of prescribed therapy, 
and 2 (10.5 %) were afraid of side effects of drugs. 
15 (25.0%) patients consciously missed the medication intake 
when they felt well (Table 1). Individual analysis showed that 
3 (20.0 %) patients had bronchial obstruction of I degree 
(FEV1 (91.5 ± 3.0) % of pred.), 5 (33.3 %) patients – 
bronchial obstruction of II degree (FEV1 (66.3 ± 5.4) % 
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pred.), 6 (40.0 %) patients– bronchial obstruction of III degree 
(FEV1 (41.3 ± 2.3) % pred.) and only 1 (6.7 %) patient – 
bronchial obstruction of IV degree (FEV1 25.6 % pred.). 
Correlation analysis between the level of FEV1 and missed 
medication intake in patients with COPD because of feeling 
well revealed the reliable relationship (r = - 0.238, p < 0.05). 
The latter indicates that the greater the severity of bronchial 
obstruction is, the higher becomes the patient’s adherence to 
inhalation therapy. 
The data showed that 10 (16.7 %) patients felt hassled about 
sticking to the treatment plan (Table 1), where 7 (70.0 %) 
patients were male. Most likely, this is due to the fact that 
women are more disciplined as to drug therapy, than men. 
To the fourth question «When you travel or leave home, do 
you sometimes forget to bring along your medicine?», 51 
(85.0 %) respondents answered negatively (Table 1). During 
the individual interviews of patients, it was found that the vast 
majority of them (58 (96.7 %) out of 60 patients) generally do 
not leave anywhere from the place of residence. In this regard, 
this question for patients with COPD living in our region 
cannot be taken into account. 
The result of answers to the fifth question of MMAS-8 
showed that 51 (85.0 %) patients responded to it positively 
(Table 1). However, it is possibly due to the physician’s 
reminder of a visit the next day, therefore patients took the 
inhaled treatment to improve the results of the examination. 
The least number of patients (7 (11.7 %) out of 60) 
independently stopped or reduced the dosage of 
recommended inhalation therapy, because they felt bad after 
it’s administering (Table 1). Correlation analysis showed the 
direct reliable relationship between termination or reduction 
of drug therapy intake and the development of side effects 
from these medications (r = 0.385, p < 0.001). 
 
4. Conclusions 
1. The level of adherence of COPD patients depends on the 
regularity of contact with the doctor and does not depend 
on gender. 
2. The main cause of non-adherence of COPD patients is 
the fact that sometimes patients forget to take medication, 
among other reasons there are major financial difficulties. 
3. The risk group as to the reduced adherence to inhalation 
therapy includes patients with vague bronchial 
obstruction. 
4. Given the difficulty of obtaining adequate responses to 
some questions of MMAS-8, one should consider the 
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